When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Prolactinoma

Evidence last reviewed: 18 Oct 2026
Topic last updated: 12 Nov 2026

Summary

Definition

History and exam

Key diagnostic factors

  • amenorrhea or oligomenorrhea
  • infertility
  • galactorrhea
  • loss of sexual desire (libido)
  • erectile dysfunction
  • visual deterioration
Full details

Other diagnostic factors

  • osteoporosis
Full details

Risk factors

  • female sex, 20-50 years of age
  • genetic predisposition
Full details

Diagnostic tests

1st tests to order

  • serum prolactin
  • pituitary MRI
  • computerized visual field exam
Full details

Treatment algorithm

ONGOING

premenopausal women

postmenopausal women

men: microadenoma or macroadenoma

refractory or aggressive prolactinoma

Contributors

Authors

Niamh Martin, MB ChB, PhD, FRCP

Professor of Endocrinology

Imperial Centre for Endocrinology

Department of Metabolism, Digestion and Reproduction

Imperial College London

London

UK

Disclosures

NM declares that she has no competing interests.

Acknowledgements

Professor Niamh Martin would like to gratefully acknowledge Dr Ilan Shimon, the previous contributor to this topic.

Disclosures

IS receives consultancy and lecturing fees from Pfizer, Israel, and is an author of a number of references cited in this topic.

Peer reviewers

Mark Molitch, MD

Professor

Division of Endocrinology

Northwestern University Feinberg School of Medicine

Chicago, IL

Disclosures

MM is an author of a number of references cited in this topic.

Peer reviewer acknowledgements

BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.

Disclosures

Peer reviewer affiliations and disclosures pertain to the time of the review.

References

Our in-house evidence and editorial teams collaborate with international expert contributors and peer reviewers to ensure that we provide access to the most clinically relevant information possible.

Key articles

Fleseriu M, Varlamov EV, Akirov A, et al. Prolactin-secreting adenomas: pathogenesis, diagnosis, and management. Lancet Diabetes Endocrinol. 2025 Oct;13(10):874-90. Abstract

Auriemma RS, Pirchio R, Pivonello C, et al. Approach to the patient with prolactinoma. J Clin Endocrinol Metab. 2023 Aug 18;108(9):2400-23.Full text  Abstract

Petersenn S, Fleseriu M, Casanueva FF, et al. Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international consensus statement. Nat Rev Endocrinol. 2023 Dec;19(12):722-40.Full text  Abstract

Raverot G, Burman P, Abreu AP, et al. Revised European Society of Endocrinology clinical practice guideline for the management of aggressive pituitary tumours and pituitary carcinomas. Eur J Endocrinol. 2025 May 30;192(6):R45-78.Full text  Abstract

Luger A, Broersen LHA, Biermasz NR, et al. ESE clinical practice guideline on functioning and nonfunctioning pituitary adenomas in pregnancy. Eur J Endocrinol. 2021 Aug 23;185(3):G1-33.Full text  Abstract

Reference articles

A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.
  • Prolactinoma images
  • Differentials

    • Nonfunctioning pituitary macroadenomas
    • Drug-induced hyperprolactinemia
    • Primary hypothyroidism
    More Differentials
  • Guidelines

    • Revised European Society of Endocrinology clinical practice guideline for the management of aggressive pituitary tumours and pituitary carcinomas
    • ESE clinical practice guideline on functioning and nonfunctioning pituitary adenomas in pregnancy
    More Guidelines
  • padlock-lockedLog in or subscribe to access all of BMJ Best Practice

Use of this content is subject to our disclaimer